Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants diagnosed with Stage IIIA melanoma during identification period
Participants underwent sentinel lymph node biopsy (SLNB) (index-event) during identification period
Participants with a complete surgical resection at or following SLNB during the identification period
Participants received nivolumab, pembrolizumab or dabrafenib/trametinib as adjuvant therapy in USON post-index event during the identification period (i.e., within 12 weeks of SLNB/resection); or received no treatment during the index period
Participants receiving care at a USON site utilizing the full EHR capacities of the iKM database at the time of treatment
Participants with ≥2 visits within the USON during the observation period
Participants ≥18 years of age at first clinical diagnosis of melanoma
You may not be if
Participants with a previous systemic therapy prior to index
Participants with a diagnosis of ocular or uveal melanoma during the study period
Participants with a previous nonmelanoma cancer without complete remission for more than 3 years prior to index
Participants with mucosal or acral melanoma during the study period
Participants with systemic use of glucocorticoids during at the initiation of adjuvant therapy
Participants enrolled in a clinical trial at any time during the study period
Participants with a diagnosis and receiving treatment for another malignancy during the study observation period
